Clinical

Dataset Information

ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer


ABSTRACT: This is a Phase 1b open-label, multiple dose/schedule sequential study to determine the safety and efficacy of the oxidative phosphorylation (OxPhos) pathway inhibitor ME-344 in combination with bevacizumab in subjects with recurrent mCRC.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 47232 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR